文献速递胸部肿瘤

早期肺鳞癌预后mRNA特征的多机构前瞻性验证

Multi-Institutional Prospective Validation of Prognostic mRNA Signatures in Early Stage Squamous Lung Cancer (Alliance).
PubMed 文献 · J Thorac Oncol · 2020-07-24

研究前瞻性纳入249例(队列I)和234例(队列II)早期肺鳞癌术后患者,采用两阶段验证锁定参数与中心实验室质控,评估预后基因表达特征。队列I中三个特征经验证,其中一个在队列II中较基线临床模型显著提升预后判别(C-index差异0.122,p<0.05)。

要点

  • 一个预后mRNA特征在早期肺鳞癌中较基线临床模型显著改善风险判别。
  • 验证采用两阶段设计、中心实验室与锁定参数,提高结果稳健性。
  • 该特征有望辅助术后辅助治疗决策或临床试验分层。

核心结论

  • 一个预后mRNA特征在队列II中较基线临床模型显著提升早期肺鳞癌术后预后判别(C-index差异0.122,p<0.05)。
  • 结果为首个严格验证、可用于指导辅助治疗或临床试验的肺鳞癌检测。

研究设计与样本

  • 两阶段前瞻性验证,使用独立中心实验室、客观质控标准与锁定测试参数。
  • 队列I为机构生物样本与数据收集方案,最终纳入249例。
  • 队列II为协作组生物样本与数据收集方案,最终纳入234例。
  • 所有病例经中心化临床、病理与生物样本参数复核以确定最终纳入。
  • 主要筛选标准为特征能显著预测队列I术后3年生存,合格者进入队列II比较基线风险因素与联合特征的预测效能。

主要发现

  • 队列I中男性、高龄与更高分期与更短生存相关,并建立基线临床模型。
  • 队列I验证了三个特征,其中一个在队列II中经验证。
  • 该特征联合基线模型较单用基线模型显著改善预后判别(C-index差异0.122,p<0.05)。

关键数值与推荐

  • 主要筛选要求特征显著预测队列I术后3年生存。
  • 队列II比较基线风险因素单用与联合特征的风险预测。
  • 联合特征较基线模型的C-index差异为0.122(p<0.05)。

临床怎么用

  • 该特征可用于早期肺鳞癌术后风险分层,辅助判断辅助治疗或临床试验入组。
  • 临床应用前需结合中心化病理与样本质控流程。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Surgical resection is curative for some patients with early lung squamous cell carcinoma. Staging and clinical factors do not adequately predict recurrence risk. We sought to validate the discriminative performance of proposed prognostic gene expression signatures at a level of rigor sufficient to support clinical use. METHODS: The two-stage validation used independent core laboratories, objective quality control standards, locked test parameters, and large multi-institutional specimen and data sets. The first stage validation confirmed a signature's ability to stratify patient survival. The second-stage validation determined which signature(s) optimally improved risk discrimination when added to baseline clinical predictors. Participants were prospectively enrolled in institutional (cohort I) or cooperative group (cohort II) biospecimen and data collection protocols. All cases underwent a central review of clinical, pathologic, and biospecimen parameters using objective criteria to determine final inclusion (cohort I: n = 249; cohort II: n = 234). Primary selection required that a signature significantly predict a 3-year survival after surgical resection in cohort I. Signatures meeting this criterion were further tested in cohort II, comparing risk prediction using baseline risk factors alone versus in combination with the signature. RESULTS: Male sex, advanced age, and higher stage were associated with shorter survival in cohort I and established a baseline clinical model. Of the three signatures validated in cohort I, one signature was validated in cohort II and statistically significantly enhanced the prognosis relative to the baseline model (C-index difference 0.122; p < 0.05). CONCLUSIONS: These results represent the first rigorous validation of a test appropriate to direct adjuvant treatment or clinical trials for patients with lung squamous cell carcinoma.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Bueno R, Richards WG, Harpole DH, et al. Multi-Institutional Prospective Validation of Prognostic mRNA Signatures in Early Stage Squamous Lung Cancer (Alliance). J Thorac Oncol. 2020. PMID: 32717408. doi:10.1016/j.jtho.2020.07.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。